Immunotherapy has transformed the management of many malignancies, yet a substantial proportion of patients either fail to respond or eventually develop ...

The intersection of neuroimmunology and neurodegeneration has advanced considerably in recent years, with particular interest focused on the role of the ...

Gene-edited regulatory B cells could suppress overactive immune responses, potentially helping in the treatment of autoimmune ...

Full abstracts are available online on the ASCO website.

Rheumatoid arthritis (RA) susceptibility is strongly influenced by genetic variations within the major histocompatibility ...

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

Across the immunity cycle, NPs can co-deliver tumor antigens and adjuvants to DCs, enhance major histocompatibility complex class I (MHC-I)-mediated cross-presentation, and promote cytotoxic T ...

Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...

A recent Views & Comments article published in Engineering highlights advances in repurposing influenza viruses as flexible ...

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines—an advance that could lead to much ...

COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the ...